Gearing Up for Biosimilars

Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.

Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field. Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.

Download BioPharm International's

2017 Outsourcing Resources eBook

.

Articles in this issue

over 8 years ago

Article

Customer Relationship Management in Contract Manufacturing

over 8 years ago

Article

Preparing an Approach to Cold Chain for Cell- and Tissue-Based Therapies

over 8 years ago

Article

Getting Biopharmaceutical Tech Transfer Right the First Time

over 8 years ago

Article

CMOs Tackle New Challenges

over 8 years ago

Article

Insourcing vs Outsourcing: Choosing the Right Strategy

over 8 years ago

Article

Operations and Quality Oversight of CMOs

over 8 years ago

Article

Quality Metrics and CMO Agreement

over 8 years ago

Article

Key Considerations in Outsourced “On-Site” Audits as Part of Supplier Qualification

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!